Objective: Hair concentrations are a noninvasive measure of cumulative antiretroviral exposure and the strongest predictor of viral suppression in large cohorts of nonpregnant patients. We examined hair concentrations of antiretrovirals in relation to virologic outcomes in pregnant and breastfeeding women for the first time.
Introduction
The World Health Organization (WHO) now recommends combination antiretroviral therapy (ART) for pregnant and breastfeeding HIV-infected women at all CD4 þ cell counts [1] . This policy promises to preserve maternal health and reduce HIV transmission to infants [2] if adequate antiretroviral exposure and viral suppression can be achieved throughout pregnancy, breastfeeding, and beyond. During pregnancy, barriers to drug adherence and physiologic changes that alter antiretroviral pharmacokinetics may result in reduced drug exposure, thereby placing women at risk for virologic failure and infants at risk for HIV acquisition [3] [4] [5] [6] .
Hair concentrations are a noninvasive, quantitative measure of cumulative antiretroviral exposure that integrate the effects of adherence and pharmacokinetics. In cohorts in North America and South Africa, antiretroviral hair concentrations were strong predictors of viral suppression and predicted subsequent virologic failure among patients with inadequate drug exposure [7] [8] [9] . However, studies of the utility of measuring antiretroviral hair concentrations during pregnancy and breastfeeding, when antiretroviral pharmacokinetics can be dynamic with respect to drug absorption, distribution, metabolism, and elimination, have not previously been conducted. Drug concentrations in hair offer several advantages over other measures of antiretroviral adherence and exposure. Whereas single plasma drug levels record exposure over the prior 24-48 h and may vary significantly from day-to-day, antiretroviral hair concentrations reflect uptake from the systemic circulation over weeks to months [10] [11] [12] [13] [14] . Hair samples can be collected without specialized training or equipment and stored and shipped at room temperature. Furthermore, hair concentrations and other pharmacologic measures do not rely on patient self-report (which is subject to recall and social desirability biases) and are less susceptible to transient improvements in adherence prior to clinic/ study visits than plasma measures [15] [16] [17] [18] .
Given the potential consequences of inadequate antiretroviral exposure during pregnancy and breastfeeding for both mother and infant, there is a pressing need for an objective, quantifiable measure of antiretroviral adherence and exposure during these periods, particularly in resource-limited settings. We present the first analysis of hair concentrations of antiretrovirals among pregnant and breastfeeding women in relation to virologic outcomes. We examined this association in a cohort of women randomized to efavirenz or lopinavir/ritonavirbased ART, which are now considered first-line and second-line regimens, respectively, by the WHO for HIV-infected adults globally, including pregnant women.
Methods

Study design and population
We conducted a secondary analysis of the Prevention of Malaria and HIV Disease in Tororo (PROMOTE)-Pregnant Women and Infants study (ClinitalTrials.gov, NCT00993031), an open-label randomized trial designed to test the hypothesis that lopinavir would reduce placental malaria rates. The trial was conducted in Tororo, in rural Uganda, from December 2009 to March 2013. We have previously reported on the results of the primary malaria endpoint, pregnancy outcomes, ART efficacy and safety, and the use of antiretroviral hair concentrations to assess mother-to-infant transfer of antiretrovirals [19] [20] [21] [22] .
HIV-infected, ART-naive pregnant women at 12-28 weeks gestation were enrolled in PROMOTE regardless of CD4 þ cell count. Participants were randomized to initiate lopinavir/ritonavir or efavirenz-based combination ART and continue through 1 year postpartum. Participants received lamivudine/zidovudine 150 mg/ 300 mg twice daily and either efavirenz 600 mg once daily or lopinavir/ritonavir 200 mg/50 mg two tablets twice daily, increased to three tablets twice daily from 30 weeks gestation until delivery. One participant randomized to lopinavir switched to efavirenz due to the need for concomitant tuberculosis treatment; all other participants remained on their assigned study drug, regardless of subsequent viral loads. AbbVie Pharmaceuticals (North Chicago, Illinois, USA) provided lopinavir/ritonavir (Aluvia), but had no other role in the study. The study protocol was approved by the Makerere University School of Medicine Research and Ethics Committee, the Uganda National Council of Science and Technology, and the University of California, San Francisco Committee on Human Research; all participants provided written informed consent in their preferred language.
Measurements HIV-1 RNA was measured at screening, delivery, and 24 weeks postpartum, using standardized assays, as previously described [19] . The primary outcome for this analysis was viral suppression (plasma HIV-1 RNA 400 copies/ml, based on the lower limit of detection of the assay) at delivery and 24 weeks postpartum, with a 2-week measurement window for the latter. Adherence was assessed by self-reported recall over the 3 days prior to each study visit and analyzed as a continuous predictor.
Small hair samples were collected using previously described methods [7] at 30-34 weeks gestation and 10-25 weeks postpartum. Women were on antiretrovirals for at least 4 weeks prior to hair collection. Efavirenz and lopinavir hair concentrations were measured via liquid chromatography/tandem mass spectrometry (LC/MS/ MS) after extraction and assessed as continuous variables. Methods to analyze lopinavir and efavirenz levels in hair have been described previously [9, 13, 23 ]. These methods have been validated for lopinavir and efavirenz from 0.05 to 20 ng drug/mg hair, with good linearity (r 2 >0.99) and reproducibility (coefficients of variation <15%) [24] .
Statistical analysis
Multivariate logistic regression models examined predictors of viral suppression at delivery (among women on ART 6 weeks) and 24 weeks postpartum. Models were chosen by forward stepwise selection of predictors, with self-reported adherence included in all models. The high rates of self-reported adherence resulted in wide confidence intervals for its effect on viral suppression and, for the efavirenz group, precluded meaningful estimates at delivery. An exact logistic regression model was run for the efavirenz arm at delivery (which produced similar results to those reported below) because of the small number of participants without viral suppression at this time point. For women with more than one hair specimen available postpartum, we used the level measured on the specimen closest to the 24-week time point. The hair concentration used in the models at delivery was interpolated or extrapolated from a mixedeffects repeated measures model [25] that accounted for weeks of gestation or weeks since delivery, duration on the higher third-trimester dose for women on lopinavir/ ritonavir, and a random person effect. Because of few virologic failures, we decided a priori to use antiretroviral hair concentration as a continuous predictor; addition of quadratic terms revealed no strong evidence for departures from linearity (all P > 0.60). Statistical analyses were performed using SAS software versions 9.2 and 9.4 (SAS Institute, Cary, North Carolina, USA).
Results
Characteristics of study participants
Of 389 women in this study, 325 provided hair samples (162 in the efavirenz arm and 163 in the lopinavir/ ritonavir arm). The acceptability of hair collection was 84%. Among women who provided hair samples, clinical characteristics at enrollment were similar between the two study arms, including median CD4 þ cell count [efavirenz: 373 cells/ml (range 14-1080); lopinavir: 358 cells/ml (range 81-1030)], and median log 10 HIV-1 RNA [efavirenz: 4.3 copies/ml (range 2.6-4.9); lopinavir: 4.1 copies/ml (range 2.6-5.9)] prior to ART initiation ( Table 1) . At 24 weeks postpartum, 87.5% of women were breastfeeding their infants. One infant acquired HIV during the course of the study. The mean (and range) hair concentrations of efavirenz and lopinavir are shown in Table 1 . Mean self-reported adherence was greater than 97% for women in both arms at delivery and 24 weeks postpartum.
Virologic outcomes
At delivery, 98.0% of women in the efavirenz arm and 87.4% of women in the lopinavir arm achieved viral suppression (P < 0.001). Median time from ART initiation to delivery was 16.9 weeks (range 4.6-27.9) in the efavirenz arm and 17.7 weeks (range 3.9-27.1) in the lopinavir arm. At 24 weeks postpartum, 92.5% of women on efavirenz and 90.6% of women on lopinavir were virologically suppressed (P ¼ 0.57).
Of the 20 participants on lopinavir with detectable viral loads at delivery, 17 had viral loads measured at 24 weeks postpartum; three participants had detectable viral loads at both time points. The three women on efavirenz who had detectable viral loads at delivery did not have viral load measurements at 24 weeks postpartum, although two had undetectable viral loads at other postpartum time points that were not included in this analysis.
Predictors of viral suppression
Hair concentrations of efavirenz and lopinavir at 30-34 weeks gestation were significantly associated with viral suppression at delivery [ In multivariate models, including self-reported adherence and pretreatment HIV-1 RNA, antiretroviral hair concentrations were the strongest predictor of viral suppression at delivery [efavirenz: adjusted OR (aOR) 1.86 per doubling, 95% CI 1.14-3.1, P ¼ 0.013; lopinavir: aOR 1.90 per doubling, 95% CI 1.33-2.7, P ¼ 0.0004] and 24 weeks postpartum (efavirenz: aOR 1.81 per doubling, 95% CI 1.22-2.7, P ¼ 0.003; lopinavir: aOR 1.53 per doubling, 95% CI 1.05-2.2, P ¼ 0.026). The mean (range) hair concentrations among participants with detectable versus undetectable viral loads at delivery and postpartum for each antiretroviral are provided in the footnotes to Table 1 . Self-reported adherence was not statistically significantly associated with virologic outcomes for either drug in multivariate models.
Discussion
In this cohort of HIV-infected pregnant and breastfeeding women in rural Uganda, hair concentrations of efavirenz and lopinavir were the strongest predictors of viral suppression at delivery and 24 weeks postpartum in multivariate models, surpassing self-reported adherence and pretreatment HIV-1 RNA levels as predictors. Moreover, the acceptability and feasibility of hair collection were high. To our knowledge, this is the first study to report on antiretroviral concentrations in hair samples in relation to virologic outcomes during pregnancy and breastfeeding among HIV-infected women. We have previously demonstrated strong associations between antiretroviral hair concentrations and viral suppression in nonpregnant populations [7, 8, 26 ], but the current study has implications for monitoring treatment outcomes relevant to both maternal and infant health during high-risk periods for perinatal transmission and during periods of pharmacokinetic flux.
The higher rate of viral suppression observed at delivery among women in this substudy who were randomized to the efavirenz-containing regimen is consistent with published results from the parent study [19] . Self-reported perfect adherence was high in both arms (>97%), but was not statistically significantly associated with virologic outcomes, consistent with known limitations of selfreport [17, 27] . Pretreatment HIV RNA level is a common predictor of subsequent outcomes [28] , and was associated with lower rates of viral suppression in our study as well.
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AIDS 2015, Vol 29 No 7 Weeks since ART initiation is reported for all study participants. Participants on ART for fewer than 6 weeks at the time of delivery were excluded from models of viral suppression at delivery. Several studies have reported that hair collection is acceptable among HIV-infected patients in resourcelimited settings and that antiretroviral hair concentrations could be useful for treatment management or in research studies. In a cohort of HIV-infected adults in rural Kenya, hair collection was feasible and highly acceptable (>95%) and costs less than an HIV viral load test in the region [16] . A recent study from two phase II preexposure prophylaxis trials in Kenya and Uganda also demonstrated high acceptability (>95%) for hair collection [29] . A study in South Africa found that low lopinavir levels in hair were associated with virologic failure among patients on second-line ART [9] . Given the well known limitations of current methods to monitor adherence, hair levels, which integrate adherence and variations in pharmacokinetics, may become useful tools in the peripartum setting. Of note, in this study, adaptively searching for threshold hair levels for predicting virologic failure would have been likely to produce overfitting of this limited dataset. Further studies by our group in a larger cohort of pregnant and breastfeeding women will allow us to define such thresholds. Finally, the hair assays used for this study have been standardized and validated using LC/MS/MS, but widespread applicability, especially in clinical settings, will rely on the availability of modified hair assays, currently under development [30] , harnessing lower cost technology.
Close monitoring of antiretroviral exposure during pregnancy and breastfeeding may help to ensure the critical outcome of virologic suppression in mothers.
Measuring drug exposure during this time, when pharmacokinetic parameters can vary, may be important for predicting and influencing outcomes. In this cohort of childbearing HIV-infected women, hair concentrations of antiretrovirals were the strongest predictor of viral suppression. Hair concentrations of antiretrovirals could serve as an innovative tool for optimizing maternal health and minimizing the risk of perinatal HIV transmission. 
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